Carzelesin

Drug Profile

Carzelesin

Alternative Names: NSC D 619020; U 80244

Latest Information Update: 28 Nov 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pharmacia Corporation
  • Class Antineoplastics
  • Mechanism of Action DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Malignant melanoma; Non-Hodgkin's lymphoma; Ovarian cancer; Solid tumours

Most Recent Events

  • 28 Nov 2000 A phase II study has been added to the Cancer therapeutic trials section
  • 27 Oct 1998 Discontinued(II) for cancer in Europe
  • 06 Jan 1998 Discontinued-II for Breast cancer in European Union (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top